Histogenics Corp Company Profile (NASDAQ:HSGX)

About Histogenics Corp (HSGX)

Histogenics Corp logoHistogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company's product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient's own cartilage cells through a series of tissue engineering processes. The patient's cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company's Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: HSGX
  • CUSIP: N/A
Key Metrics:
  • Previous Close: $1.68
  • 50 Day Moving Average: $1.72
  • 200 Day Moving Average: $2.19
  • 52-Week Range: $1.39 - $4.47
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.40
  • P/E Growth: 0.00
  • Market Cap: $34.68M
  • Outstanding Shares: 15,868,000
  • Beta: 1.33
Profitability:
  • Return on Equity: -188.90%
  • Return on Assets: -95.93%
Debt:
  • Debt-to-Equity Ratio: 0.08%
  • Current Ratio: 5.30%
  • Quick Ratio: 5.30%

Analyst Ratings

Consensus Ratings for Histogenics Corp (NASDAQ:HSGX) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $5.88 (249.70% upside)

Analysts' Ratings History for Histogenics Corp (NASDAQ:HSGX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/20/2017HC WainwrightSet Price TargetBuy$4.00HighView Rating Details
1/23/2017Canaccord GenuitySet Price TargetBuy$5.00N/AView Rating Details
9/19/2016Needham & Company LLCBoost Price TargetBuy$8.00 -> $11.00N/AView Rating Details
9/7/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
8/11/2016BTIG ResearchUpgradeNeutral -> Buy$3.50N/AView Rating Details
11/13/2015Cowen and CompanyLower Price TargetOutperform$17.00 -> $12.50N/AView Rating Details
(Data available from 3/25/2015 forward)

Earnings

Earnings History for Histogenics Corp (NASDAQ:HSGX)
Earnings by Quarter for Histogenics Corp (NASDAQ:HSGX)
Earnings History by Quarter for Histogenics Corp (NASDAQ:HSGX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017        
3/16/2017Q4 2016($0.45)($0.63)ViewN/AView Earnings Details
11/10/2016Q316($0.49)($0.70)ViewListenView Earnings Details
8/11/2016Q216($0.60)($0.61)ViewListenView Earnings Details
5/12/2016Q116($0.59)($0.60)ViewListenView Earnings Details
3/10/2016Q415($0.59)($0.63)ViewListenView Earnings Details
11/12/2015Q315($0.47)($0.61)ViewListenView Earnings Details
8/12/2015Q215($0.49)($0.58)ViewListenView Earnings Details
5/14/2015Q115($1.34)($0.60)ViewListenView Earnings Details
2/26/2015Q414$0.66$1.70ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Histogenics Corp (NASDAQ:HSGX)
Current Year EPS Consensus Estimate: $-1.45 EPS
Next Year EPS Consensus Estimate: $-1.20 EPS

Dividends

Dividend History for Histogenics Corp (NASDAQ:HSGX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Histogenics Corp (NASDAQ:HSGX)
Insider Ownership Percentage: 16.00%
Institutional Ownership Percentage: 45.98%
Insider Trades by Quarter for Histogenics Corp (NASDAQ:HSGX)
Institutional Ownership by Quarter for Histogenics Corp (NASDAQ:HSGX)
Insider Trades by Quarter for Histogenics Corp (NASDAQ:HSGX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2016David N GillDirectorBuy3,000$1.65$4,950.00View SEC Filing  
12/9/2016David N GillDirectorBuy5,000$1.92$9,600.00View SEC Filing  
12/2/2016Jonathan I LieberCFOBuy5,000$1.95$9,750.00View SEC Filing  
12/1/2016Adam GridleyInsiderBuy5,000$2.01$10,050.00View SEC Filing  
9/29/2016Split Rock Partners Ii, LpMajor ShareholderBuy276,801$2.25$622,802.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Histogenics Corp (NASDAQ:HSGX)
Latest Headlines for Histogenics Corp (NASDAQ:HSGX)
Source:
DateHeadline
americanbankingnews.com logoHC Wainwright Analysts Give Histogenics Corp (HSGX) a $4.00 Price Target
www.americanbankingnews.com - March 24 at 7:50 AM
americanbankingnews.com logoHistogenics Corp (HSGX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 23 at 12:16 PM
americanbankingnews.com logoHistogenics Corp (HSGX) Given a $4.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 21 at 3:40 PM
finance.yahoo.com logoEdited Transcript of HSGX earnings conference call or presentation 16-Mar-17 12:30pm GMT
finance.yahoo.com - March 17 at 6:00 PM
benzinga.com logoHistogenics Corporation Announces Financial and...
www.benzinga.com - March 16 at 4:24 PM
seekingalpha.com logoHistogenics' (HSGX) CEO Adam Gridley on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 16 at 4:24 PM
us.rd.yahoo.com logoHistogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2016
us.rd.yahoo.com - March 16 at 4:24 PM
biz.yahoo.com logoQ4 2016 Histogenics Corp Earnings Release - Before Market Open
us.rd.yahoo.com - March 16 at 4:24 PM
americanbankingnews.com logoHistogenics Corp (HSGX) Releases Quarterly Earnings Results, Misses Estimates By $0.18 EPS
www.americanbankingnews.com - March 16 at 10:43 AM
us.rd.yahoo.com logoHistogenics Announces Publication of Biomechanical and Structural Data From Human Engineered Cartilage Testing
us.rd.yahoo.com - March 9 at 3:50 PM
us.rd.yahoo.com logo8:36 am Histogenics announces the publication in the Journal of Orthopaedic Research of a peer-reviewed publication entitled Mechanical Properties and Structure-Function Relationships of Human Chondrocyte-Seeded Cartilage Constructs After I
us.rd.yahoo.com - March 9 at 3:50 PM
finance.yahoo.com logoHistogenics Corporation to Announce 2016 Financial Results on March 16, 2017
finance.yahoo.com - March 2 at 6:07 PM
finance.yahoo.com logoHistogenics Corporation to Present at Upcoming Investor Conferences
finance.yahoo.com - February 23 at 5:46 PM
finance.yahoo.com logoZimmer Biomet (ZBH) Q4 Earnings: A Surprise in the Cards?
finance.yahoo.com - February 8 at 11:25 PM
finance.yahoo.com logoWill Thermo Fisher (TMO) Beat Earnings Estimates in Q4?
finance.yahoo.com - February 8 at 11:25 PM
finance.yahoo.com logoQuest Diagnostics (DGX) Q4 Earnings: What Lies in Store?
finance.yahoo.com - January 16 at 9:01 AM
streetinsider.com logoHistogenics (HSGX) Announces Publication of MRI Data From NeoCart Phase 1, Phase 2
www.streetinsider.com - January 13 at 11:57 PM
finance.yahoo.com logoStock Market Roundup, Jan. 12: AMZN Jobs, FCAU Cheating, AKS & X Tank
finance.yahoo.com - January 12 at 6:13 PM
finance.yahoo.com logoHistogenics Announces Publication of MRI Data From NeoCart® Phase 1 and Phase 2 Clinical Trials in the American Journal of Sports Medicine
finance.yahoo.com - January 11 at 6:24 PM
finance.yahoo.com logo4:06 pm Histogenics announces an online publication in the American Journal of Sports Medicine; results from the two studies indicate that NeoCart is a safe & effective treatment for articular cartilage lesions through 5-year follow-up
finance.yahoo.com - January 11 at 6:24 PM
finance.yahoo.com logoCoverage initiated on Histogenics by H.C. Wainwright
finance.yahoo.com - December 19 at 11:45 AM
biz.yahoo.com logoHISTOGENICS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
biz.yahoo.com - November 21 at 10:36 AM
finance.yahoo.com logoHISTOGENICS CORP Financials
finance.yahoo.com - November 18 at 4:58 PM
finance.yahoo.com logoEdited Transcript of HSGX earnings conference call or presentation 10-Nov-16 1:30pm GMT
finance.yahoo.com - November 11 at 5:02 PM
streetinsider.com logoForm 8-K HISTOGENICS CORP For: Nov 10
www.streetinsider.com - November 10 at 4:54 PM
nasdaq.com logoHistogenics Corporation Announces Third Quarter 2016 Financial and Operating Results
www.nasdaq.com - November 10 at 4:54 PM
biz.yahoo.com logoQ3 2016 Histogenics Corp Earnings Release - Before Market Open
biz.yahoo.com - November 10 at 4:54 PM
biz.yahoo.com logoHISTOGENICS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - November 10 at 4:54 PM
wsj.com logo[$$] Sweden's BoneSupport Taps Medtech Entrepreneur O'Donnell for U.S. Post
www.wsj.com - November 8 at 11:00 PM
finance.yahoo.com logoHistogenics Corporation to Announce Third Quarter 2016 Financial Results on November 10, 2016
finance.yahoo.com - October 27 at 10:13 AM
finance.yahoo.com logoHistogenics Corporation to Ring the Nasdaq Stock Market Closing Bell
finance.yahoo.com - October 13 at 8:41 AM
finance.yahoo.com logoHistogenics Corporation (Nasdaq: HSGX), to Ring The Nasdaq Stock Market Closing Bell
finance.yahoo.com - October 12 at 10:36 AM
finance.yahoo.com logoHistogenics Corporation Announces Addition of Dr. Lawrence Bonassar of Cornell University to Its Scientific Advisory Board
finance.yahoo.com - October 6 at 5:23 PM
finance.yahoo.com logoHistogenics Corporation to Present at the 2016 Cell & Gene Meeting on the Mesa
finance.yahoo.com - September 26 at 10:07 AM
streetinsider.com logoHistogenics (HSGX) Enters $30M Private Placement
www.streetinsider.com - September 16 at 5:20 PM
nasdaq.com logoHistogenics Corporation Announces $30.0 Million Private Placement
www.nasdaq.com - September 16 at 9:25 AM
biz.yahoo.com logoHISTOGENICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti
biz.yahoo.com - September 16 at 9:25 AM
finance.yahoo.com logoHistogenics Corporation to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - August 31 at 10:17 AM
seekingalpha.com logoHistogenics' (HSGX) CEO Adam Gridley on Q2 2016 Results - Earnings Call Transcript
seekingalpha.com - August 12 at 5:34 PM
streetinsider.com logoBTIG Upgrades Histogenics Corp. (HSGX) to Buy
www.streetinsider.com - August 12 at 5:34 PM
finance.yahoo.com logoBTIG Upgrades Histogenics To Buy, Sets $3.50 Price Target
finance.yahoo.com - August 12 at 5:34 PM
finance.yahoo.com logoEdited Transcript of HSGX earnings conference call or presentation 11-Aug-16 12:30pm GMT
finance.yahoo.com - August 12 at 8:37 AM

Social

Frequently Asked Questions for Histogenics Corp (NASDAQ:HSGX)

What is Histogenics Corp's stock symbol?

Histogenics Corp trades on the NASDAQ under the ticker symbol "HSGX."

How were Histogenics Corp's earnings last quarter?

Histogenics Corp (NASDAQ:HSGX) posted its quarterly earnings data on Thursday, March, 16th. The company reported ($0.63) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $0.18. During the same quarter in the previous year, the firm earned ($0.63) earnings per share.

When will Histogenics Corp make its next earnings announcement?

Histogenics Corp is scheduled to release their next quarterly earnings announcement on Wednesday, May, 10th 2017.

Where is Histogenics Corp's stock going? Where will Histogenics Corp's stock price be in 2017?

5 brokerages have issued 1-year target prices for Histogenics Corp's shares. Their predictions range from $3.50 to $11.00. On average, they expect Histogenics Corp's share price to reach $5.88 in the next twelve months.

When did Histogenics Corp IPO?

(HSGX) raised $60 million in an IPO on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

Who owns Histogenics Corp stock?

Histogenics Corp's stock is owned by many different of retail and institutional investors. Top institutional investors include Third Security LLC (16.96%), Perceptive Advisors LLC (11.20%), FMR LLC (10.90%), Armistice Capital LLC (7.97%), Palo Alto Investors LLC (1.91%) and Renaissance Technologies LLC (0.62%). Company insiders that own Histogenics Corp stock include Adam Gridley, David N Gill, Jonathan I Lieber and Split Rock Partners Ii, Lp.

Who sold Histogenics Corp stock? Who is selling Histogenics Corp stock?

Histogenics Corp's stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC.

Who bought Histogenics Corp stock? Who is buying Histogenics Corp stock?

Histogenics Corp's stock was acquired by a variety of institutional investors in the last quarter, including Third Security LLC, Perceptive Advisors LLC, Armistice Capital LLC and Renaissance Technologies LLC. Company insiders that have bought Histogenics Corp stock in the last two years include Adam Gridley, David N Gill, Jonathan I Lieber and Split Rock Partners Ii, Lp.

How do I buy Histogenics Corp stock?

Shares of Histogenics Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Histogenics Corp stock cost?

One share of Histogenics Corp stock can currently be purchased for approximately $1.68.

Histogenics Corp (HSGX) Chart for Saturday, March, 25, 2017

This page was last updated on 3/25/2017 by MarketBeat.com Staff